Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Sucheta Telang, Mary Ann Rasku, Amy L Clem, Karen Carter, Alden C Klarer, Wesley R Badger, Rebecca A Milam, Shesh N Rai, Jianmin Pan, Hana Gragg, Brian F Clem, Kelly M McMasters, Donald M Miller, Jason Chesney, Sucheta Telang, Mary Ann Rasku, Amy L Clem, Karen Carter, Alden C Klarer, Wesley R Badger, Rebecca A Milam, Shesh N Rai, Jianmin Pan, Hana Gragg, Brian F Clem, Kelly M McMasters, Donald M Miller, Jason Chesney

Abstract

Background: We previously found that administration of an interleukin 2/diphtheria toxin conjugate (DAB/IL2; Denileukin Diftitox; ONTAK) to stage IV melanoma patients depleted CD4(+)CD25(HI)Foxp3(+) regulatory T cells and expanded melanoma-specific CD8(+) T cells. The goal of this study was to assess the clinical efficacy of DAB/IL2 in an expanded cohort of stage IV melanoma patients.

Methods: In a single-center, phase II trial, DAB/IL2 (12 μg/kg; 4 daily doses; 21 day cycles) was administered to 60 unresectable stage IV melanoma patients and response rates were assessed using a combination of 2-[(18)F]-fluoro-2-deoxy-glucose (FDG)-positron emission tomography (PET) and computed tomography (CT) imaging.

Results: After DAB/IL2 administration, 16.7% of the 60 patients had partial responses, 5% stable disease and 15% mixed responses. Importantly, 45.5% of the chemo/immuno-naïve sub-population (11/60 patients) experienced partial responses. One year survival was markedly higher in partial responders (80 ± 11.9%) relative to patients with progressive disease (23.7 ± 6.5%; p value < 0.001) and 40 ± 6.2% of the total DAB/IL2-treated population were alive at 1 year.

Conclusions: These data support the development of multi-center, randomized trials of DAB/IL2 as a monotherapy and in combination with other immunotherapeutic agents for the treatment of stage IV melanoma.

Trial registration: NCT00299689.

Figures

Figure 1
Figure 1
Examples of partial and mixed responses after DAB/IL2 administration. A. Anterior/posterior and lateral views of PET imaging reveal a large duodenal mass (arrow) and several hepatic metastases (box) at baseline and 1 month after the final cycle of DAB/IL2. PET imaging confirmed regression of the hepatic metastases (right panels) and a modest reduction in the duodenal mass. The increased 18 F-fluorodeoxyglucose uptake in the left kidney is due to hydronephrosis which is unrelated to melanoma. B. After 3 cycles of DAB/IL2, this patient experienced the marked regression of a large subcutaneous and a pelvic mass (see bottom 2 horizontal red arrows just above the bladder [which normally contains tracer]) and a peritoneal mass (right vertical arrow). Simultaneously, enlarged paratracheal lymph nodes worsened (upper arrows), a large conglomeration of left axillary masses expanded (dashed circle). An inferior peritoneal mass appeared and expanded (left vertical arrow) and a superior peritoneal mass expanded and then regressed with treatment (upper horizontal arrow).
Figure 2
Figure 2
Durable responses after DAB/IL2 administration. On the left, baseline anterior/posterior views of FDG-PET imaging reveal multiple FDG-avid melanoma metastases in three clinical examples: A, 78 year-old female; B, 47 year-old male; and C, 62 year-old male. After DAB/IL2 administration, we observed a clinically significant and durable reduction in tumor burden, including hepatic metastases, pulmonary nodules, metatastic lymph nodes and subcutaneous nodules in all three patient examples.
Figure 3
Figure 3
A. Increased partial responses to DAB/IL2 noted in chemo/immuno-naïve and stage M1A melanoma patients. Sixty stage IV melanoma patients were administered DAB/IL2 and the objective response rates were determined using qualitative radiological assessments of FDG-PET and CT imaging. Whereas 16.7% of all treated patients experienced partial responses, 45.5% of the chemo/immuno-naïve patients experienced partial responses (A). Response rates were calculated based on sub-stage of melanoma. Whereas stage M1A (lymph node, skin and subcutaneous) (B) melanoma patients experienced the highest total objective response rate, stage M1B patients had no partial responses (C) and chemo/immuno-naïve patients with visceral metastases (stage M1C) had a > 60% partial response rate (D).
Figure 4
Figure 4
High overall survival in chemo/immuno-naïve, stage M1A and partial responders to DAB/IL2. Median overall survival of these patients was determined using the Kaplan-Meier method and stratified based on prior treatment exposure (A), stage (M1A-C) (B) and response rate (C).

References

    1. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA. et al.Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527–534.
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.
    1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M. et al.High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–2116.
    1. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.
    1. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–2458.
    1. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, Mackie R. et al.Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117–126.
    1. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, Jr, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. pp. 155–164.
    1. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med.
    1. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295–307.
    1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151–1164.
    1. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol. 2008;20(2):241–246.
    1. Jones E, Dahm-Vicker M, Golgher D, Gallimore A. CD25+ regulatory T cells and tumor immunity. Immunol Lett. 2003;85(2):141–143.
    1. Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2002;2:1.
    1. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 2004;200(6):771–782.
    1. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173(2):1444–1453.
    1. Foss FM. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000;1(Suppl 1):S27–31.
    1. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol. 2005;54(6):369–377.
    1. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007;110(9):3192–3201.
    1. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM. et al.Transient T cell depletion causes regression of melanoma metastases. J Transl Med. 2008;6(1):1–18.
    1. Gottlieb RH, Litwin A, Gupta B, Taylor J, Raczyk C, Mashtare T, Wilding G, Fakih M. Qualitative radiology assessment of tumor response: does it measure up? Clin Imaging. 2008;32(2):136–140.
    1. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005;28(6):582–592.
    1. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest. 2007;117(5):1167–1174.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj